secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0001104659-24-124881
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus to divest UDENYCA franchise to Intas for up to $558.4M; plans to repay convertible notes
--------------------------------------------------------------------------------

- Upfront cash $483.4M (subject to inventory adj.) plus up to $75M in net sales milestones ($37.5M each at $300M and $350M thresholds).
- Proceeds to fully repay $230M 1.5% convertible notes due April 2026 and buy out $49.1M royalty obligation on UDENYCA.
- Post-close cash runway over 2 years; focus shifts to immuno-oncology pipeline (LOQTORZI, casdozokitug, CHS-114).
- Transaction requires shareholder approval, HSR, CFIUS; expected close Q1 2025; board unanimously recommends.
- Coherus to provide Q4 2024 sales and Q1 2025 cash guidance in early January 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465924124881/0001104659-24-124881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465924124881/tm2429853d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-124881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer